Author:
Ma Xiaohui,Chang Lina,Li Shuo,Gu Yian,Wan Jieying,Sang Hequn,Ding Li,Liu Ming,He Qing
Funder
the National Natural Science Foundation of China
Tianjin Key Medical Discipline (Specialty) Construction Project
Major Project of Tianjin Municipal Science and Technology Bureau
Publisher
Springer Science and Business Media LLC
Reference49 articles.
1. European Association for the Study of the Liver (EASL). European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL-EASD-EASO clinical practice guidelines on the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). Obes Facts. 2024;:1–70.
2. Song SJ, Lai JC-T, Wong GL-H, Wong VW-S, Yip TC-F. Can we use old NAFLD data under the new MASLD definition? J Hepatol. 2024;80:e54–6.
3. Driessen S, Francque SM, Anker SD, Castro Cabezas M, Grobbee DE, Tushuizen ME, et al. Metabolic dysfunction-associated steatotic liver disease and the heart. Hepatol Baltim Md. 2023. https://doi.org/10.1097/HEP.0000000000000735.
4. Younossi ZM, Paik JM, Stepanova M, Ong J, Alqahtani S, Henry L. Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease. J Hepatol. 2024;80:694–701.
5. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatol Baltim Md. 2016;64:73–84.